Name: Real Psychiatry: Education Designed for and by APPs on the Frontlines of Modern Practice
Start: 13/01/2024 01:00 PM +00:00
End: 13/01/2024 09:15 PM +00:00

<ul>
<li>The state of mental health care</li>
<li>What you can expect from this conference</li>
</ul>

Carmen Kosicek, MSN, APNP, PMHNP-BC (Chair)

Welcome Address

DEBUNKING POLYPHARMACY:&nbsp;AN UPDATED VIEW OF MOOD DISORDERS AS OVERLAPPING DISEASE SPECTRUMS
<ul>
<li>How overlap in symptomology (e.g., MDD, MDD-MF, BD depression, BD mania, schizoaffective disorder) and prevalence of co-occurrence complicates or simplifies medication selection&nbsp;</li>
<li>Potential adverse effects of psychiatric polypharmacy and their mechanistic drivers</li>
<li>Cleaning up the med list: How to deprescribe excess medications and prioritize appropriate treatments in patients with overlapping conditions</li>
</ul>
FORMAT:&nbsp;
Connecting the dots between symptoms and treatment through case-based problem solving

Shannon Eaton, MSN, APN, PMHNP-BC

Amber Hoberg, MSN, APRN, PMHNP-BC

Karen Greene

Intersecting Indications: The Challenges and Opportunities of  Clinical Overlap in Upgrading Patient Management

PART 1: UNIQUE ATTRIBUTES OF ORAL STRATEGIES
<ul>
<li>Pharmacokinetics, metabolism, and dosing (e.g., short/long-acting, half-life)</li>
<li>&nbsp;Side effect profiles and comorbid considerations</li>
</ul>
PART 2: THE ROLE OF LONG-ACTING INJECTABLES
<ul>
<li>Pharmacokinetics, metabolism, and dosing; onset of action</li>
<li>Side effect profiles and considerations for patient adherence</li>
<li>Administration protocols (e.g., initiation&nbsp;vs maintenance use, frequency)</li>
</ul>
PART 3: CREATING A CROSS-TITRATION PLAN: THE ART OF SWITCHING AND STOPPING&nbsp; ANTIPSYCHOTIC MEDICATIONS
&nbsp;
FORMAT
"GLOVES OFF&rdquo; Discussion on pros and cons of provider&rsquo;s medication selection and preferences.

Shawn P. Gallagher, PhD, PMHNP-BC, PMHCNS-BC, FNP-BC

Christina Fuchs, DNP, PMHNP- BC

Tina Matthews-Hayes, DNP, FMP-C, PHMNP-B

Atypical: Modern Pharmacokinetic/dynamic Considerations with Antipsychotics

Wellness & Networking Break

PART 1: WRITING AND ADVOCATING FOR THE PA
<ul>
<li>&nbsp;Most commonly denied antipsychotic medications</li>
<li>Types of PAs and how to navigate them</li>
<li>Show Them the Data! The what, when, and why of appeals</li>
</ul>
PART 2: THE PHARMACY STRATEGY
<ul>
<li>Step by Step Editing: Circumventing &ldquo;step therapy&rdquo;/tier requirements</li>
<li>Know Your Pharmacy: &ldquo;Big box&rdquo; vs independent vs specialty pharmacy requirements/options</li>
<li>A guide to super couponing in pharmaceuticals</li>
</ul>
FORMAT
Creating individual, actionable road&nbsp;maps to breach fiscal barriers to&nbsp;medication access
**Subsequent sessions&nbsp;will include&nbsp;&ldquo;Prior Authorizations (PA)&nbsp;Tips&rdquo; by disease that&nbsp;attendees can add to&nbsp;an interactive&nbsp;roadmap handout**

Bobbi Jo Durst, MSN, APNP, PMHNP- BC

Chelsea Schwartz, MSN, APRN, PMHNP-BC

Road Map to Access: Tools for Real-World Fiscal Obtainability of the Medications Your Patient Really Needs

PART 1: THE HIDDEN SIDE OF SCHIZOPHRENIA
<ul>
<li>The role of cognitive and negative symptoms on medication adherence and disease trajectory</li>
</ul>
PART 2: DATA-DRIVEN DECISION-MAKING
<ul>
<li>Improving patient experience and outcomes with new mechanisms and practical developments of emerging strategies - DEVELOPMENT HIGHLIGHTS: LAI dose preparation, reduced breakthrough symptoms</li>
<li>&nbsp;Approaches to balancing treatment of positive, negative, and cognitive symptoms - AGENT HIGHLIGHTS: cariprazine, lumateperone</li>
<li>Pharmacist Quick Tip (video): advice and experience from a real PharmD</li>
</ul>
FORMAT
Showcasing the impact of SZ on patient families and community

The Real Schizophrenia: Using Modern Strategies to Address the Full Spectrum of the Patient and Caregiver Experience

PART 1: OLD HABITS DIE HARD: DO ANTIDEPRESSANTS STILL HAVE A ROLE IN BD&nbsp;DEPRESSION?
PART 2: WHAT&rsquo;S RELEVANT AND WHAT&rsquo;S NOT WHEN CHOOSING BETWEEN BD DEPRESSION MEDICATIONS
<ul>
<li>Efficacy and safety data leading to recent medication approvals (cariprazine, lumateperone)</li>
<li>FDA-indicated medications and selecting between options</li>
<li>Wordsmithing medication selection and changes with patients</li>
</ul>
FORMAT
Illustrating challenging&nbsp;prescribing choices through case-based&nbsp;problem solving
CONDITION-SPECIFIC&nbsp;PA TIPS
(e.g., compatible ICD-10 codes)
&nbsp;

Mia W. Jones, MSN, APRN, PMHNP-BC

Turning the Tide in Bipolar Depression

PART 1: MAKE A CALL: DIFFERENTIATING EXTRAPYRAMIDAL SYMPTOMS AND THEIR IMPACT
(e.g., drug-induced parkinsonism (DIP), tardive dyskinesia (TD), dystonia, akathisia)
PART 2: MAKE A LINK: PHARMACOTHERAPY ASSOCIATIONS WITH EMERGENT EPS
(e.g., first vs second generation antipsychotics, combinations)
PART 3: MAKE A MOVE: VMAT2 INHIBITORS FOR TD
(e.g., mechanisms, dosing, contraindications, risk of parkinsonism)
PART 4: MAKE A PLAN: THE IMPORTANCE OF DISTINCT&nbsp;MANAGEMENT APPROACHES BETWEEN EPS
(e.g., risks with anticholinergics, antipsychotic discontinuation)
<ul>
<li>Pharmacist Quick Tip: inducers versus inhibitors and consequences of medication mismanagement</li>
</ul>
FORMAT
Case-by-case examination and resolution of treatment-emergent movement disorders
CONDITION-SPECIFIC&nbsp;PA TIPS
(e.g., compatible&nbsp;ICD-10 codes)

Extrapyramidal Symptoms: When are They Tardive Dyskinesia?

PART 1: SHIFTING CONVENTION: NEW AND MULTITARGETED MECHANISMS
<ul>
<li>Pros and Cons of SSRIs/SNRIs: When and how to break ties</li>
<li>Examining better ways to target diverse pathology and minimize side effects -&nbsp;New/emerging and multimodal mechanisms (e.g., dextromethorphan-bupropion, zuranolone, esketamine, ulotaront) - Adjunctive antipsychotics (e.g., cariprazine, lumateperone)</li>
</ul>
PART 2: MODERN PARADIGMS FOR PHARMACOTHERAPY
<ul>
<li>Treatment approaches for depression and its many phenotypes&nbsp;</li>
</ul>
&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;- Monitoring therapeutic response
&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;- Is there a place for PMX?&nbsp;
FORMAT
Use real cases to show where&nbsp;classic convention goes wrong and where new strategies fit in
CONDITION-SPECIFIC&nbsp;PA TIPS
(e.g., Dextromethorphan-bupropion&nbsp;PA guide)
&nbsp;

Leslie Citrome, MD, MPH

The Changing Face of Major Depressive Disorder Treatment: New Paradigms and Emerging Strategies

PART 1: A DIFFERENT LENS &ndash; APPROACHING PEDIATRIC VS ADULT PATIENTS
<ul>
<li>Differences in presentations between children and adults</li>
<li>Where ADHD falls when prioritizing treatments in patients with multiple psychiatric conditions</li>
</ul>
PART 2: MODERN CHALLENGES WITH USE OF STIMULANTS
<ul>
<li>Increasing over-prescription of stimulants and its consequences: role of telehealth companies, pharmacy delay/block of prescriptions</li>
</ul>
PART 3: A CHANGE OF PACE - EVOLVING TREATMENT OPTIONS
<ul>
<li>Which mix? Differentiating traditional and new mixed salts</li>
<li>Considerations (e.g., onset of action, long-acting) for age-&nbsp;and lifestyle-based treatment needs</li>
<li>Cardiovascular effects and optimal monitoring (e.g., EKG/ECG)</li>
</ul>
FORMAT
Stimulating comparison&nbsp;of expert and peer&nbsp;strategies for challenging management decisions
CONDITION-SPECIFIC&nbsp;PA TIPS
Check for manufacturer&nbsp;savings programs!
&nbsp;
&nbsp;

Ann Barbaro

Mark Jankelow, MSN, BA, PMHNP-BC

Attention to Detail: Optimizing ADHD Treatment Across Patient Lifespan

MEDICATION-ASSISTED TREATMENT OF SUDS
Overview of Standard of Care and Emerging Therapeutics
<ul>
<li>Standard of care for outpatient acute opioid withdrawal (e.g., titrating opioids, lofexidine)</li>
<li>Wordsmithing new medications to patients</li>
</ul>
Detailed Patient Selection for OUD Treatment Options
<ul>
<li>Buprenorphine/naloxone formulations (e.g., sublingual tablets/film, ER injection)</li>
<li>Optimal prescribing strategies (e.g., X-waiver requirements, quick-start guide for in-office induction (samhsa.gov))</li>
</ul>
Addressing systemic effects of opioids: differences in bioavailability, taste, dissolve time, impact on risk of&nbsp;parenteral abuse
FORMAT
Modern data-driven approaches to matching patients to optimal treatment plans

Engaged and Committed: Building Successful Patient-Centered Substance Use Disorders Treatment

REFLECTION OF WHAT HAS BEEN LEARNED AND HOW IT CAN BE IMPLEMENTED IN INDIVIDUAL ATTENDEE MARKETS&nbsp;
<ul>
<li>CONTINUE TO LEARN!</li>
</ul>

Closing Remarks

Jasper Cayanga, RPh

Amy De Guzman, RPh

Era Cassandra I. Lopez, RPh

Primary Theme-Copy

English

(UTC -04:00) Eastern Time (US & Canada - EDT)

America/New_York

<script>
 window.__lc = window.__lc || {};
 window.__lc.license = 12377808;
 ;(function(n,t,c){function i(n){return e._h?e._h.apply(null,n):e._q.push(n)}var e={_q:[],_h:null,_v:"2.0",on:function(){i(["on",c.call(arguments)])},once:function(){i(["once",c.call(arguments)])},off:function(){i(["off",c.call(arguments)])},get:function(){if(!e._h)throw new Error("[LiveChatWidget] You can't use getters before load.");return i(["get",c.call(arguments)])},call:function(){i(["call",c.call(arguments)])},init:function(){var n=t.createElement("script");n.async=!0,n.type="text/javascript",n.src="https://cdn.livechatinc.com/tracking.js",t.head.appendChild(n)}};!n.__lc.asyncInit&&e.init(),n.LiveChatWidget=n.LiveChatWidget||e}(window,document,[].slice))
</script>
<noscript><a href="https://www.livechat.com/chat-with/12377808/" rel="nofollow">Chat with us</a>, powered by <a href="https://www.livechat.com/?welcome" rel="noopener nofollow" target="_blank">LiveChat</a></noscript>

Sessions

Speakers16 Speakers

Carmen Kosicek, MSN, APNP, PMHNP-BC (Chair)

Ann Barbaro

Leslie Citrome, MD, MPH

Bobbi Jo Durst, MSN, APNP, PMHNP- BC

Shannon Eaton, MSN, APN, PMHNP-BC

Christina Fuchs, DNP, PMHNP- BC

Shawn P. Gallagher, PhD, PMHNP-BC, PMHCNS-BC, FNP-BC

Karen Greene

Amber Hoberg, MSN, APRN, PMHNP-BC

Mark Jankelow, MSN, BA, PMHNP-BC

Mia W. Jones, MSN, APRN, PMHNP-BC

Tina Matthews-Hayes, DNP, FMP-C, PHMNP-B

Chelsea Schwartz, MSN, APRN, PMHNP-BC

Jasper Cayanga, RPh

Amy De Guzman, RPh

Era Cassandra I. Lopez, RPh

Sessions

Speakers.css-ikqgdo{margin:0;font-size:1.4rem;font-weight:500;line-height:1.5;color:#3c81a2;font-family:'Poppins',sans-serif;margin-left:0.8rem;}16 Speakers

Carmen Kosicek, MSN, APNP, PMHNP-BC (Chair)

Ann Barbaro

Leslie Citrome, MD, MPH

Bobbi Jo Durst, MSN, APNP, PMHNP- BC

Shannon Eaton, MSN, APN, PMHNP-BC

Christina Fuchs, DNP, PMHNP- BC

Shawn P. Gallagher, PhD, PMHNP-BC, PMHCNS-BC, FNP-BC

Karen Greene

Amber Hoberg, MSN, APRN, PMHNP-BC

Mark Jankelow, MSN, BA, PMHNP-BC

Mia W. Jones, MSN, APRN, PMHNP-BC

Tina Matthews-Hayes, DNP, FMP-C, PHMNP-B

Chelsea Schwartz, MSN, APRN, PMHNP-BC

Jasper Cayanga, RPh

Amy De Guzman, RPh

Era Cassandra I. Lopez, RPh

Speakers16 Speakers